Walid Macaron
Overview
Explore the profile of Walid Macaron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nassar A, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40032601
Background: Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods: This is an international...
2.
Zhao Y, Short N, Kantarjian H, Chang T, Ghate P, Qu C, et al.
Blood
. 2024 Mar;
144(1):61-73.
PMID: 38551807
Inotuzumab ozogamicin (InO) is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells. In a retrospective cohort of InO-treated patients with B-cell acute lymphoblastic leukemia, we sought to understand the...
3.
Nassar A, El-Am E, Denu R, Abou Alaiwi S, El Zarif T, Macaron W, et al.
JACC CardioOncol
. 2024 Mar;
6(1):71-79.
PMID: 38510282
Background: Primary cardiac soft tissue sarcomas (CSTS) affect young adults, with dismal outcomes. Objectives: The aim of this study was to investigate the clinical outcomes of patients with CSTS receiving...
4.
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory -Mutated AML
Short N, Daver N, DiNardo C, Kadia T, Nasr L, Macaron W, et al.
J Clin Oncol
. 2024 Jan;
42(13):1499-1508.
PMID: 38277619
Purpose: Azacitidine plus venetoclax is a standard of care for patients with newly diagnosed AML who are unfit for intensive chemotherapy. However, mutations are a common mechanism of resistance to...
5.
Zhao Y, Short N, Kantarjian H, Chang T, Ghate P, Qu C, et al.
medRxiv
. 2023 Dec;
PMID: 38106221
Key Points: We identified multiple mechanisms of CD22 antigen escape from inotuzumab ozogamicin, including protein truncation, protein destabilization, and epitope alteration.Hypermutation caused by error-prone DNA damage repair was a driver...
6.
Short N, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, et al.
J Hematol Oncol
. 2023 Jul;
16(1):73.
PMID: 37422688
Background: Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedistat...
7.
Zerdan M, Kassab J, Saba L, Haroun E, Zerdan M, Allam S, et al.
Front Oncol
. 2023 May;
13:1173701.
PMID: 37228488
Minimal residual disease (MRD) assessment using peripheral blood instead of bone marrow aspirate/biopsy specimen or the biopsy of the cancerous infiltrated by lymphoid malignancies is an emerging technique with enormous...
8.
Short N, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, et al.
Am J Hematol
. 2023 May;
98(8):1196-1203.
PMID: 37183966
Reverse transcription polymerase chain reaction (RT-PCR) for BCR::ABL1 is the most common and widely accepted method of measurable residual disease (MRD) assessment in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL);...
9.
Jabbour E, Short N, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al.
Lancet Haematol
. 2022 Nov;
10(1):e24-e34.
PMID: 36402146
Background: Ponatinib and blinatumomab are effective therapies in patients with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia, and their combination might be a promising treatment option. In this study, we aimed...
10.
Jabbour E, Short N, Jain N, Thompson P, Kadia T, Ferrajoli A, et al.
Lancet Haematol
. 2022 Oct;
9(12):e878-e885.
PMID: 36279879
Background: Blinatumomab is effective in relapsed or refractory B-cell acute lymphocytic leukaemia and results in high rates of minimal residual disease negativity. We aimed to establish whether the incorporation of...